1. Home Page
  2. About the OSUCCC – James
  3. Publications and Reports
  4. Magazines and Publications
  5. Frontiers
  6. 2020
  7. Winter
  8. Gene Mutation Combinations Predict AML Outcomes in Older Patients
Winter

Gene Mutation Combinations Predict AML Outcomes in Older Patients

A study led by researchers at the OSUCCC – James identified combinations of gene mutations that predict whether an older person with acute myeloid leukemia (AML) might achieve complete remission when treated with standard chemotherapy.

Gene Mutation Combinations Predict AML Outcomes in Older Patients

    The researchers analyzed the AML cells of 423 patients age 60 and older for mutations in 80 cancer- or leukemia-associated genes, then used that information to classify patients into groups that had a good, poor or intermediate outcome after treatment with standard chemotherapy.

    The study highlighted the extremely poor outcome of AML patients aged 60 and older with current treatments. However, the authors found mutation combinations that associated with patient survival, some of which were different than those known to be associated with outcome in younger AML patients.

    “This study is important because the majority of research in AML is done in patients under age 60, even though the majority of AML patients are of older age,” says study leader Clara D. Bloomfield, MD, a Distinguished University Professor at Ohio State who also serves as cancer scholar and senior adviser to the OSUCCC – James. Bloomfield notes that the findings might refine the classification of older AML patients who are to be treated with chemotherapy.

    “We found that the number and types of chromosome changes and gene mutations are different in older AML patients compared with younger patients, along with the significance of some of those abnormalities,” Bloomfield says. “So it’s important that we evaluate older AML patients separately from younger patients.”

    First author and OSUCCC – James researcher Ann-Kathrin Eisfeld, MD, a member of Ohio State’s Internal Medicine/Physician-Scientist Training Program, says the favorable complete response rate of the good-risk group did not lead to better overall survival.

    Of patients in the good-risk group, 82% experienced relapse, as did patients in the intermediate-risk group. “And those groups did only slightly better than the poor-risk group, where 93% of patients relapsed,” Eisfeld says. “This tells us that, once patients are in remission, they probably require additional or different treatment than chemotherapy alone to extend remission or potentially cure those patients.

    “Our findings suggest that older AML patients should be tested for additional gene mutations before receiving standard chemotherapy,” Eisfeld adds.

    Published in the journal Leukemia.